Brian Dorsey
CIK 1380762 · Chief Operating Officer · last filed 2026-01-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$61.2K
Companies
4
Total Filings
56
Lifetime Open-Market Net
-$2.70M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SPRY | Chief Operating Officer | 10,789 | $5.67 | $61.2K | -$1.82M | 8 | 2026-01-05 |
| SEELOS THERAPEUTICS, INC. (APRI) Delisted | SVP, Chief Development Officer | 5,304 | — | — | $10.5K | 13 | 2018-09-04 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | SVP Research | 6,243 | — | — | $0 | 2 | 2014-10-10 |
| Pernix Sleep, Inc. (SOMX) Delisted | SVP, Technical Operations | 52,264 | — | — | -$887.0K | 28 | 2013-01-03 |
Recent Filings · Page 2 of 6
56 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-04 | SPRY | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | SPRY | Grant (A) | — | $0 | EDGAR |
| 2018-09-04 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Mixed | +38,550 | -$14.3K | EDGAR |
| 2018-01-03 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Mixed | −5,485 | -$10.1K | EDGAR |
| 2017-09-07 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Tax (F) | −14,093 | -$22.0K | EDGAR |
| 2017-06-05 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2017-03-24 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Tax (F) | −1,495 | -$4.2K | EDGAR |
| 2017-01-06 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +75,000 | $0 | EDGAR |
| 2016-05-20 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | +250,000 | $0 | EDGAR |
| 2016-05-20 | SEELOS THERAPEUTICS, INC. (APRI) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.